Our Research Journey

From garden herbs to breakthrough discoveries

2025 in Focus

Deciphering the Mechanism of Our First Drug Candidate

In 2025, NYB reached a defining scientific milestone by uncovering the mechanism of action behind its first lead drug candidate. Laboratory studies confirmed how the compound works at the molecular level, validating its therapeutic pathway and paving the way for future clinical trials and regulatory submission. This achievement marked a crucial step in transforming years of discovery into tangible therapeutic potential.

NB-A002: Precision Therapy Targeting Cancer’sGenetic Weaknesses

NB-A002 is designed to strike at the hidden weakness of cancer. It targets ILF2, a key protein that helps cancer cells remove harmful nucleic acid structures called R-loops. By blocking this resolving process, NB-A002 overwhelms cancer cells with DNA damage they cannot rectify, especially those already weakened by genetic defects in DNA repair pathways.Healthy cells, with intact repair systems, remain protected from NB-A002. This breakthrough shifts cancer treatment from targeting the tumor origin to focusing on its genetic vulnerabilities, ushering in a new era of precision therapy that truly matches the right treatment to the right patient

Showcasing Innovation at GITEX ASIA 2025

From April 23–25, 2025, NYB.AI presented its advancements in AI-driven drug discovery and biomanufacturing at GITEX ASIA 2025, held at Marina Bay Sands, Singapore. As Asia’s premier technology and innovation showcase, the event highlighted NYB’s growing leadership at the crossroads of biotechnology and artificial intelligence.

Global Recognition at SuperAI Genesis

On July 14, 2025, NYB.AI earned 1st Prize at the SuperAI Genesis Startup Competition, standing out among over700 startups across 100 countries. The recognition celebrated the innovation behind NYB.AI’s DTIGN platform, which combines graph neural networks and molecular docking to accurately predict drug–target interactions — particularly in compounds derived from Southeast Asia’s rich biodiversity.

This global achievement reinforced NYB’s belief that the future of medicine lies where nature’s diversity meets the precision of AI — a vision that continues to guide its pioneering work.

Nanyang Biologics with RF Acquisition Corp II pursue US$1.5 Billion Nasdaq listing

On October 2, 2025, Nanyang Biologics (NYB) announced a US$1.5 billion business combination with RF Acquisition Corp II (NASDAQ: RFAI) to pursue a Nasdaq listing under “NYB”. The deal marks a key step toward bringing NYB’s AI-driven drug discovery platform, Vecura™ AI, and its nature-inspired therapeutic pipeline to global markets.

For NYB, 2025 was more than a year of milestones. It was a year of momentum — where science met purpose, innovation found its voice, and a vision for a healthier future came into clearer focus.